Take two patients, both 78 kg, both 5'7”, both with a BMI of around 27 — technically “overweight”, not obese. One European, one Indian. The European is largely metabolically healthy; the Indian is twice as likely to already have insulin resistance, fatty liver, and an elevated risk of heart disease.

This isn't a coincidence. It's called the South Asian phenotype, and it's why Indian medical guidelines use different cut-offs than the WHO standard ones.

The metabolic difference, in three numbers

Visceral fat at same BMI
≈ 20% more
South Asians carry more fat around abdominal organs than Caucasians at equivalent BMI — and visceral fat is the metabolically dangerous kind.
Diabetes risk threshold
BMI 23
The Indian Council of Medical Research (ICMR) flags type-2 diabetes risk at BMI 23 — well below the WHO obesity cut-off of 30.
Waist circumference cut-off
90/80 cm
Men > 90 cm, women > 80 cm = central obesity (Indian cut-offs). Western thresholds are 102/88 cm.

Indian BMI categories (not the WHO ones)

Indian endocrinology guidelines, adopted by ICMR and the Indian Obesity Society, classify body weight as:

  • Underweight: BMI < 18.5
  • Normal: BMI 18.5–22.9
  • Overweight: BMI 23–24.9
  • Obesity I: BMI 25–29.9
  • Obesity II: BMI ≥ 30

The WHO “overweight” category starts at 25. In India, you cross into clinical obesity at 25. That's a real difference when you're deciding whether someone qualifies for medical weight management.

Why does this happen?

Two reasons get the most evidence:

  • Genetic predisposition to thrifty metabolism.Indian populations evolved through cycles of food scarcity. The metabolism that survived was efficient at storing fat — helpful then, problematic now.
  • Lower lean muscle mass at equivalent BMI.A 75 kg Indian on average has less muscle and more fat than a 75 kg Caucasian, even if BMI is identical. Muscle is metabolically active tissue; less muscle = lower baseline insulin sensitivity.

Lifestyle (urbanisation, sedentary work, diet shift to refined carbs and ultra-processed food) accelerates the underlying risk, but it doesn't explain why the same lifestyle is more damaging to Indians than to other populations.

What it means for who qualifies for GLP-1 therapy

Indian Endocrine Society and Diabetes India guidelines support considering pharmacological weight management at:

  • BMI ≥ 27 with at least one weight-related condition (pre-diabetes, type 2 diabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnoea, or PCOS),
  • BMI ≥ 30 even without comorbidities,
  • Or waist circumference ≥ 90 cm (men) / ≥ 80 cm (women) with at least one comorbidity.

That's why our qualification check includes waist measurement, not just weight + height. A BMI of 26 with a 100 cm waist and fatty liver is a stronger case than a BMI of 30 with a 92 cm waist and no comorbidity.

The takeaway

If you're Indian, the BMI calculator on a generic Western health website will probably under-diagnose your risk. Your medical team should be using India-specific cut-offs, asking about waist circumference, and screening for pre-diabetes and fatty liver even if your weight looks “not that bad” on the global standard.

The 5-minute qualification check below uses the Indian guideline cut-offs — not the WHO ones — so the answer it gives you is the answer an Indian endocrinologist would give.

Sources
  • ICMR-INDIAB nationwide diabetes prevalence study (2017–2023).
  • Misra A et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians. JAPI 2009;57:163-170.
  • Endocrine Society of India: Adult Obesity Management Guidelines 2022 revision.